Major Players are Thermo Fisher Scientific (U.S.), Molecular Devices (U.S.), Perkin Elmer (U.S.), GE Healthcare Lifesciences (U.K), and Merck Millipore (Germany)
(PRWEB) April 04, 2014
The “High Content Screening Market by Instruments (Cell Imaging and Analysis System) by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2018” analyzes and studies the major market drivers, restraints, andopportunities in North America, Europe, Asia, and the Rest of the World (RoW).
Browse more than 50 market data tables with 10 figures spread through 151 pages and in-depth TOC on "High Content Screening Market"
Early buyers will receive 10% customization on this report.
This report studies the global high content screening market over the forecast period of 2013 to 2018. The global high content screening market was valued at an estimated $362.2 million in 2013 and is expected to reach $615.8 million by 2018, growing at a CAGR of 11.2% from 2013 to 2018.
Download Free PDf Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=42710391
The HCS service market showcases a lucrative growth potential. This market includes services related to various phases of drug discovery such as target identification and target validation, primary screening, secondary screening and toxicity studies, and compound profiling among others. Among these services, primary screening represents the new revenue pocket for the HCS market.
Across the globe, the adoption of high content screening for primary screening is increasing due to factors such as increased throughput, enhanced accuracy, and ease of use. A number of automated HCS instruments are available in the market. Moreover, market players are engaged in developing new automated HCS instruments with higher throughput, which will help the market grow further.
Inquiry Before Buying @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=42710391
Taking into consideration the growing demand for HCS products, various venture capitalists are now investing in this market. For instance, in November 2011, the Entrepreneurs Fund (U.K.) and Sham (France) invested $10 million in Cytoo SA (France), a company that offers products and services for high content analysis, cell-based assays, and cell screening processes. Furthermore, in October 2011, Kernel Capital invested $1.11 million (€800 thousand) in Biocroi Ltd., a company that develops multi-well microplates for high content screening. In addition, various companies in Europe are focusing on collaborations in order to enhance their expertise in the high content screening technology. For instance, in December 2013, Evotec Technologies (Germany) and QIAGEN (Netherlands) signed an agreement to promote the advantages of combining QIAGEN’s RNAi products with Evotec’s Opera high content screening platform. This will enable researchers to carry out high-quality gene analysis. All these factors have presented an array of opportunities for the high content screening market to flourish in the coming years.
Growth in the HCS market is likely to be centered on China, Japan, Singapore, and India. Major medical automation players are investing in Asia in order to strengthen their sales and distribution networks in small Asian cities. Moreover, various research studies are being carried out in the Asian region to develop innovative products. For instance, in June 2013, Thermo Fisher Scientific invested $20 million to open a new factory in Suzhou (China), in order to meet the needs of the life sciences customers for laboratory consumables and equipment. Furthermore, new foreign entrants are collaborating with local research institutes to develop and commercialize their products in the Asian market. For instance, in June 2012, GE Healthcare (U.K.) collaborated with BGI (China) to conduct research on stem cell-derived assays for drug discovery and toxicity testing applications. Under this collaboration, GE Healthcare provided its IN Cell Analyzer 2000 system to BGI for high content imaging analysis. Such collaborations are likely to propel the growth of this market in the coming years.
Browse Related Reports:
Next Generation Sequencing (NGS) Market [Platforms (Illumina HiSeq, MiSeq, Life Technologies Ion Proton/PGM, 454 Roche), Bioinformatics (RNA-Seq, ChIP-Seq), (Pyrosequencing, SBS, SMRT), (Diagnostics, Personalized Medicine)] – Global Forecast to 2017
Top 10 Drug Discovery Technologies Market – Strategic Analysis and Global Forecasts (2010 to 2015)
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotive and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, healthcare IT, medical devices, pharmaceuticals, semiconductor and electronics, aerospace & defense.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets